ACADIA Pharmaceuticals Inc.
ACAD
शेयरों में रैंक
#4430
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
शेयर मूल्य
$20.42
अंतिम समन्वयन: 2026-10-20
मार्केट कैप
$3.52B
बदलाव (1 दिन)
3.13%
बदलाव (1 वर्ष)
-3.99%
देश
US
व्यापार ACADIA Pharmaceuticals Inc. (ACAD)
श्रेणी
Healthcare
ACADIA Pharmaceuticals Inc. (ACAD) के लिए P/B अनुपात
October 2026 को P/B अनुपात TTM: 2.53
ACADIA Pharmaceuticals Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/B अनुपात (TTM) 2.53 है। 2023 के अंत में, कंपनी का P/B अनुपात 11.88 था।
ACADIA Pharmaceuticals Inc. के लिए 2000 से 2026 तक P/B अनुपात का इतिहास
हर वर्ष के अंत में P/B अनुपात
| वर्ष | P/B अनुपात | परिवर्तन |
|---|---|---|
| 2026 (TTM) | 2.53 | -39.08% |
| 2024 | 4.15 | -65.07% |
| 2023 | 11.88 | 84.80% |
| 2022 | 6.43 | -7.18% |
| 2021 | 6.93 | -48.37% |
| 2020 | 13.41 | 48.93% |
| 2019 | 9.01 | 110.82% |
| 2018 | 4.27 | -61.19% |
| 2017 | 11.01 | 70.82% |
| 2016 | 6.45 | -64.11% |
| 2015 | 17.96 | 80.01% |
| 2014 | 9.98 | -15.17% |
| 2013 | 11.76 | 291.77% |
| 2012 | 3.00 | 24.44% |
| 2011 | 2.41 | 54.65% |
| 2010 | 1.56 | -61.80% |
| 2009 | 4.08 | 547.88% |
| 2008 | 0.63 | -81.58% |
| 2007 | 3.42 | -6.39% |
| 2006 | 3.65 | -33.64% |
| 2005 | 5.51 | 141.07% |
| 2004 | 2.28 | -1,330.93% |
| 2003 | -0.19 | -23.53% |
| 2002 | -0.24 | -153.56% |
| 2001 | 0.45 | -242.26% |
| 2000 | -0.32 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए P/B अनुपात
| कंपनी | P/B अनुपात | P/B अनुपात में अंतर | देश |
|---|---|---|---|
| 6.251 | 147.25% |
US
|
|
| 13.2547 | 424.27% |
US
|
|
| 4.208 | 66.44% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 144.54% |
NL
|
